{"name":"Carna Biosciences, Inc.","slug":"carna-biosciences-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Docirbrutinib","genericName":"Docirbrutinib","slug":"docirbrutinib","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Docirbrutinib","genericName":"Docirbrutinib","slug":"docirbrutinib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxOTFRWdk1faWotclNmbkphcC1XeHJ0R0s0UnkyYnF6LVBrQjEycDZJSERQZnk4ZktwUTBHbG1wVTFSU1FxOHVTWUx3WTFnd2I3VlpnWDVEbUVEU05NN29zWlA3ZkFkMWU3YmotRno2S29NdUhWRTJadnc3SzFacVhnTjRwODJENnZXYVh4QzYxSjIwMG4zMnNjaG94VXdRellLZW5PbkpwTnY5RGl3VTlpUW5jYmtDb09iTTg5RHQ0ZG9tTDl0Zk1GQV9nS1R5WUxsOXpkeWtRcURYVEJvQ0dmNnZZSXlYUnBobk1PYw?oc=5","date":"2025-10-06","type":"pipeline","source":"prnewswire.com","summary":"Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight - prnewswire.com","headline":"Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxOSGZaM19GR05Hdy1yY3lTS1ZGMDY2UThXSWx2LVVhUWh0N2xYTnYwdXNFU0wxRHo3alQ1T1hDZWdYZWZsbVliSXM1YXNzekprTEZPcnF3U3lYUS1aYzYwdlZ0SEprLWlFWE5vb3poZVo0ZWJnOW4zWmJHcWZYYmRyX05KdS05S0liUjJ6dGcyenBrNktkdWtWZS1BbUd1VGVNb21CYWpPWk9qc0JScHVrUzNPN1hZbVlzUUpycmxyWWtoWHc1ZDZCSU1mN1k3RExjM3BQdUthOFNiQTRxYUVVZzBLSUY1S2toR05uSjQ1U0NNVGNxNXM5WkN1cldVTWZ2dDJ3S2lOYWs3bzJHNU9lVDBWYXBzU0tF?oc=5","date":"2025-10-02","type":"trial","source":"GlobeNewswire","summary":"CRISPR Therapies Clinical Trial Pipeline Shows Potential - GlobeNewswire","headline":"CRISPR Therapies Clinical Trial Pipeline Shows Potential","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPSGhnWkIwbTRiS1BnbmdtSFhqR0QzbU4xUFQ4bnpQekdjMWdXVW1xYXVja214b2JXOGNCNV9VYVBJRDEyS0pzaGtfekxXRzZyd1M2bXpnclRMdzFYWUZvODVJSzJXcHJJUzNXRFo3ODhOQmhRc2hiMktKTDNFVjFfdUszaE8wdWFwMThDOUsxeUFyZU1XMi1Xb0dRTVFnRV9IcExRWUc5R1BZTDZjNFpObkE1TnFzdWdOQkxWcXFWSVQzLXFqNVlqMUNsUWlnUVlkOTQtU1dOUGlrN25vSXd2LUEyZDNuSGxSQVd4ZEhoRTdDM28tRmdXdzl5eHhDaG50Tzl0TWZJdW0?oc=5","date":"2025-08-27","type":"pipeline","source":"prnewswire.com","summary":"Diffuse Large B-cell Lymphoma Market to Grow at a CAGR of 13% by 2034 in Leading Markets (US, EU4, UK, and Japan) | DelveInsight - prnewswire.com","headline":"Diffuse Large B-cell Lymphoma Market to Grow at a CAGR of 13% by 2034 in Leading Markets (US, EU4, UK, and Japan) | Delv","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxNcF84NE13YXNXLVJrb3NScTZRR0ttRldKZXQ5SmJQd0tBZldEM0lNYWtnZW9FN1N5ZjhJVno3LUdad2tmUS1ZZ2tLZmZ2QnJ5dmsyQ1owVEc3cG0yd0hIS0dHaTYxZmN4aVNVX2YzOUhEQXBJUVp0eDQteUlXVkZac3g2eS1HdThac2l3WW90LVJfbkI4Rk12dUpOUE5fbnlUTDk4VzJTSlk0bk9kZmZHTGFsbEsxdkszWC1PdGlpamtfTGNMZ0hNdE5aUTBjaFpNamZPV0Y0X0VlMXJWc0hBTjRKZ1BRbU5IcmtURkRjb0RwTmxqXzRUdzZ4Q1dmaVQ4aXc5TFJBTU9Nc1Y0UXA1OTNiVzJ3U1lBZDEyRGNrS2JGM0tQbmVodnJVNmM?oc=5","date":"2024-12-03","type":"trial","source":"prnewswire.com","summary":"Lupus Nephritis Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 30+ Companies Working in the Domain - prnewswire.com","headline":"Lupus Nephritis Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 30+ C","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxQLUdGNExlVk1Yb25WMVhZWUlQUzgteV93WGRaSHU4WWZzMDFUYURLQXV5dFdHM3JTcERzSVQ5eUlLOFRSTXFsak8xdFJ4RmpHblB6YXJWY0tXMnhrQWluUk5OTkRqWTZvWHB0UkUyMndISW9XSS1tNDhnTDVnZmVxZm1lWUVLM3VVb2Y0dzJ2ZDExNWlhNk84RERxRkJSY2RubzhfSHZPZ3JpQ1NhSWV3ODltTlc3TF9ZWlV4LXFNWV9EdFlOT1RQNnFGeVotT3l3LWhmd2Z1Y19DcmtfQzJqdDlSaFlsZWJhWmlPMVluVkIzTmRPcTQxcDZ1UkhicGVfQUFqZ3QtZHVfTEQ1RXB4UmFkVkRmeXduUU1XQzM2YU5Jb002cnNpb01B?oc=5","date":"2024-11-28","type":"trial","source":"prnewswire.com","summary":"Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - prnewswire.com","headline":"Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therape","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQYXlpWWtJNGNLZHJEeWRMRnR6R0E2SVY5eElibzV2ZDlyaGZ0cDNLd3Z4V2hIVWpoZlA1LUw5SEd6SHRHbWNva1VQcUExU1FQN1lWV3pBN2M4aUktay16cGpCc2pPc2xsOWlwUzBvMXFGbmduaG5OdE1mZEM5aEdlN3BsNU1LNER4eWtScEpHb1hKUllUWm1OSndEM3MySmF6d3VPY0Q5ZVFjclBWUG5TMGNpODhhYWdiUlFQbV94T0g1T3RyZ2FnOWlhS0Z1c0xpNnExUGJBMTJfSGNGR01paGlveU5mazNqMV9JM1FIX1FlSzUwSjJ4VEtBWjVtWTVfTmpteW9n?oc=5","date":"2024-11-19","type":"regulatory","source":"prnewswire.com","summary":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight - prnewswire.com","headline":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsigh","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AJBVV95cUxOcWdtWlF4SU1sUzlOOXlKU2g1Yjh6YlYzS0ZYSlFuZHhubDhYd19Cc0V2NUFEcXlSeURLbkVzSHBSaWFEWFRKVnJKbFpkby1pa3VGR3k3UHlnOF9Gd1NlTk55WmlsQ0FMLTU4ZWNkUmF0azVRVGJYTnlaQ2g4bFFVeVI3djFZWXBNZ1BMT0MwTlVfdUZMeEZ6SW1pak1udWFHUldYLU9pemh2b0YxSGttRnBoZnd6SU9TOVl1cjAwcHRSaDRxSEQzaVBmVnFNdDFQMzhFRVNrOU9ONEdLTHB6ZDE3aGtqNTNRdF8tYXJYNWQ4cnRCVTR2cUtfa0IxVDZWa3FRa0h0UFUxMVJ5bFF0aVYybjNzb29nTWJISVEyU1g3aVhzSjRQNlV1cjJkV2FKRmd3TVVmR24wWjRrWUxOLXh6X1NqUmVMUUNIZFFxdEJTZ1ZoZmN6TFRVaWN3U0huc2tNdQ?oc=5","date":"2024-03-13","type":"deal","source":"businesswire.com","summary":"Pharmaceutical and Biotechnology Royalty Rates Report and Directory 2024: Technology Licensed, License Fees, Upfront and Milestone Payments for Deals Signed Since 2020 - ResearchAndMarkets.com - busin","headline":"Pharmaceutical and Biotechnology Royalty Rates Report and Directory 2024: Technology Licensed, License Fees, Upfront and","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOSTNwbUFOdlR3QWNORGZ2eXNBY2E5ZEpsMU5aZENzN2RhX04xWWFWYVdjX295eGdLYnFMRGhJYzFJTFBOTmp5ajhMNGRlTXQwVXhOUlNjcHhscE9SWkg5ZTVsU19xazMtQmhKNnZiZWUyUVJ1SER4M29NMzJDSFI4ME92dDZGbFFsU2xZbTQzYmI1bTZ2Ti1NaEpTY2FqVVExVmFVZHdqUlVwVzA?oc=5","date":"2023-02-23","type":"pipeline","source":"BioWorld News","summary":"Carna Biosciences and Sumitomo Pharma describe new DYRK inhibitors - BioWorld News","headline":"Carna Biosciences and Sumitomo Pharma describe new DYRK inhibitors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPWDh5QzNKTjFaa1NoN0lfRnlwbk9mTldYMnk5QnRzMU55ci0wdDB0X0ljV29kVXpfOVZaSE5LWXd6X29YN0xzM3VFM3R1XzFWR2NMaXRKbFE5YnFiakFjVHhqSE5YU1BXWFZ1dzV3aWF1SmxGZDZFa2MxX1EteC1zeXNWb0poRzBnazB1UGVPOERUdnhmNnFFQVRR?oc=5","date":"2022-09-07","type":"pipeline","source":"Fierce Biotech","summary":"Brickell Biotech deviates from old plans, rebrands for fresh start - Fierce Biotech","headline":"Brickell Biotech deviates from old plans, rebrands for fresh start","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOZU5ieFFCaG9pOFRaUnNVd3UxekFrWjlfTm5NQlB2Q01YLTBkREJtOXZNWE1oczNZeTMydlJSdGE3RzhVdVNuZmVTSEE4ODU3VUM5T0ZNaXlYODVQQWJObWxMTXhEMU8xOEVoMDhlOXV1UnRRbnR1ZTBEaFVzN1FINHJuZ0c0bGQ1eHVsTHRhYUh2djJrcjBhQVZoQVNIWUI2U3hBMkd4Rm51ckZBS3ZDYS1yYVk1MlltQVRBYQ?oc=5","date":"2006-05-19","type":"deal","source":"Technology Networks","summary":"Carna Biosciences and Enamine Sign Collaboration Agreement - Technology Networks","headline":"Carna Biosciences and Enamine Sign Collaboration Agreement","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}